

Patent

Case No.: 58327US004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	Graham, Paul D.				
Application No.:	10/79996	0	Group A		3739
Filed:	March 12, 2004		Examir	ner:	Henry M. Johnson III
Title:	Метнор	OF TATTOO REM	10VAL		
AFFIDAVIT UNDER 37 C.F.R. § 1.132					
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450		CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR § 1.8(a)] I hereby certify that this correspondence is being: I depo sited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. I transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at 571-273-8300. Signed by: Laci Burhop			
Dear Sir:					
STATE OF MINNESOTA)) ss.			
COUNTY OF R)				
Peter T. Elliott, being duly sworn, deposes and says that:					

- 1. I received a Ph.D. in Chemistry from North Dakota Statue University in 2000.
- 2. From December 2000 to present, I have been employed by 3M Company (3M), St. Paul, Minnesota, in the field of Advanced Materials Technology. I presently hold the position of Product Development Specialist, and am experienced in and familiar with pigment stability in various media and, in particular, methods of increasing and decreasing the stability of pigmented images.

I.

3. I am one of the co-inventors of the above-referenced patent application No. 10/799,960.

II.

- 4. I have read the Office Action for U.S.S.N. 10/799,960 mailed July 28, 2005.
- 5. Attached are photographs of twenty-four (24) tattoos from patients participating in a clinical study being conducted at Wake Forest University. Those marked "Aldara" have received laser treatment appropriate for the pigments contained in the tattoo and once daily application of 5% imiquimod cream to the tattooed region, beginning one week prior to the first laser treatment and continuing daily between laser therapy sessions. Those marked "control" have received laser treatment appropriate for the pigments contained in the tattoo and once daily application of vehicle cream that does not contain any biologically active agent to the tattooed region, beginning one week prior to the first laser treatment and continuing daily between laser therapy sessions.
- 6. The attached photographs represent preliminary data; those marked "pending" have not completed treatment. Nevertheless, it is apparent that some tattoos are substantially faded under the "Aldara" treatment after only one or two laser sessions. Completion of the clinical study is expected on or before the end of June 2006, including full statistical analysis of double-blinded independent evaluations of all photographs by trained dermatologists.

Further Affiant Saith Not.

Peter T. Elliott

Subscribed and sworn to before me this 28th day of December 2005



Notary Public